Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 1995
Business Overview: The Company develops, manufactures, and markets healthcare products, including contact lenses and surgical instruments, and provides healthcare services through the ownership and management of psychiatric facilities.
Key Financial Metrics
| Metric (in thousands) | Q1 1995 | Q1 1994 |
|---|---|---|
| Net Operating Revenue | $23,210 | $22,907 |
| Net Income (Loss) | $275 | $(5,150) |
| Net Income Per Share | $0.01 | $(0.17) |
| Cash and Cash Equivalents (End of Period) | $4,670 | $5,861 |
| Net Cash Used by Operating Activities | $(5,008) | $(3,375) |
| Total Debt (Current + Long-term) | $46,896 | $(Data not explicitly aggregated in text) |
| Stockholders' Deficit | $(2,834) | $(Data not explicitly aggregated in text) |
Note: The Company reported a net profit of $275,000 for the quarter, reversing a significant loss from the prior year. However, operating cash flow remained negative at $5.0 million.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenue increased slightly by 1.3% ($303,000) compared to Q1 1994. Product sales rose 7% to $12.7 million, driven by CooperVision, Inc. (CVI) and CooperSurgical, Inc. (CSI). Conversely, service revenue from Hospital Group of America (HGA) declined 5% due to managed care pressures and a dispute with Hampton Medical Group.
- Profitability Turnaround: The Company moved from a net loss of $5.15 million in Q1 1994 to a net income of $275,000 in Q1 1995. This improvement was largely driven by a $328,000 credit for dispute settlement adjustments and a $2.3 million reduction in dispute-related charges compared to the prior year.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 25% to $6.6 million, primarily due to the resolution of legal matters and reduced corporate costs. Research and development expenses also declined 8%.
- Liquidity Decline: Cash and cash equivalents decreased by $5.65 million during the quarter, despite the reported profit, due to payments for legal settlements and dispute-related costs.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management anticipates continued negative cash flows for the remainder of fiscal 1995 due to pending litigation settlements and strategic research costs. To address this, the Company drew down $3.0 million on an $8.0 million credit facility in February 1995 and is exploring asset sales, factoring, and potential stock issuances.
- Legal Risks:
- Hampton Medical Group (HMG): A significant dispute regarding alleged fraudulent billing practices at Hampton Hospital resulted in a settlement with Blue Cross and Blue Shield of New Jersey. The Company intends to seek recovery from HMG but notes no assurance of full recovery.
- Shareholder Litigation: The Company is a nominal defendant in derivative actions alleging a "trading scheme" and securities fraud. Settlement negotiations are ongoing for one class action, while another appeal is pending.
- Operational Strategy: Management is focusing on increasing hospital admissions and outpatient services to mitigate managed care pressures. Product growth is being driven by new contact lens launches (Preference Toric) and international expansion in cryosurgical products.
Investor Verification Checklist
- Cash Flow Sustainability: Verify the Company's ability to meet short-term obligations given the negative operating cash flow of $5.0 million and the reliance on a credit facility drawdown.
- Legal Settlement Finality: Confirm the status of the proposed class action settlement and the likelihood of recovering damages from Hampton Medical Group to offset Blue Cross settlement costs.
- Debt Obligations: Review the terms of the $25.3 million Senior Subordinated Secured Notes and the $9.2 million Convertible Debentures to assess refinancing risks.
- Service Revenue Trends: Monitor the impact of managed care and the Hampton Medical Group dispute on the profitability of the Hospital Group of America segment.